Outcomes of Sorafenib Therapy in Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A 12-Year Single-Center Experience

Objective: Differentiated thyroid cancer (DTC) generally has a favorable prognosis; however, resistance to radioactive iodine therapy (RAI) markedly worsens outcomes. Sorafenib is among the standard treatment options for RAI-refractory DTC. This study aimed to present our single-center experience with sorafenib therapy. Methods: The medical records of patients diagnosed with RAI-refractory DTC who were followed in the endocrinology and oncology outpatient clinics of Bursa Uludağ University Faculty of Medicine Hospital between 2010 and 2022 and treated with sorafenib were retrospectively reviewed. Progression-free survival (PFS), overall survival (OS), response rates, and adverse events profiles were analyzed. Results: Of the 19 patients included, 68.4% had papillary thyroid carcinoma and 31.6% had follicular variants. Median PFS was 16.1 months, and median OS was 36.2 months. The overall response rate was modest, while sorafenib-related adverse events occurred in 63% of patients, most commonly hand–foot syndrome (31%). Conclusion: Our single-center data suggest that sorafenib is a generally tolerable and effective therapeutic option in patients with RAI-refractory DTC, with median PFS exceeding 1 year despite frequent adverse events.